Combined Afirma Genomic Sequencing Classifier and TERT promoter mutation detection in molecular assessment of Bethesda III-VI thyroid nodules
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:131 |
|---|---|
| Enthalten in: |
Cancer cytopathology - 131(2023), 10 vom: 07. Okt., Seite 609-613 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ladenson, Paul W [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Afirma |
|---|
| Anmerkungen: |
Date Completed 04.10.2023 Date Revised 11.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cncy.22744 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360446604 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360446604 | ||
| 003 | DE-627 | ||
| 005 | 20231226083030.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cncy.22744 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360446604 | ||
| 035 | |a (NLM)37544986 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ladenson, Paul W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combined Afirma Genomic Sequencing Classifier and TERT promoter mutation detection in molecular assessment of Bethesda III-VI thyroid nodules |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.10.2023 | ||
| 500 | |a Date Revised 11.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Afirma | |
| 650 | 4 | |a TERT | |
| 650 | 4 | |a diagnosis | |
| 650 | 4 | |a molecular diagnostics | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a targeted therapy | |
| 650 | 4 | |a thyroid nodules | |
| 650 | 7 | |a TERT protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.7.49 |2 NLM | |
| 650 | 7 | |a Telomerase |2 NLM | |
| 650 | 7 | |a EC 2.7.7.49 |2 NLM | |
| 700 | 1 | |a Klopper, Joshua P |e verfasserin |4 aut | |
| 700 | 1 | |a Hao, Yangyang |e verfasserin |4 aut | |
| 700 | 1 | |a Kaushik, Praveen |e verfasserin |4 aut | |
| 700 | 1 | |a Walsh, P Sean |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Kloos, Richard T |e verfasserin |4 aut | |
| 700 | 1 | |a Ali, Syed Z |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer cytopathology |d 1999 |g 131(2023), 10 vom: 07. Okt., Seite 609-613 |w (DE-627)NLM104669381 |x 1934-6638 |7 nnns |
| 773 | 1 | 8 | |g volume:131 |g year:2023 |g number:10 |g day:07 |g month:10 |g pages:609-613 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cncy.22744 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 131 |j 2023 |e 10 |b 07 |c 10 |h 609-613 | ||